Search

Displaying results 8361 - 8370 of 10000 in total
  1. Drug

    Cry5B

    go.drugbank.com/drugs/DB17783
    Experimental

    With demonstrated anthelmintic properties, it has been investigated in the treatment of parasitic intestinal infections.[A259372, A259377] … Cry5B is a pore-forming crystal protein produced by and derived from the soil bacterium _Bacillus thuringiensis_.

  2. Drug

    N,N-dimethylarginine

    go.drugbank.com/drugs/DB01686
    Experimental

    It is a metabolic by-product of continual protein modification processes in the cytoplasm of all human cells which is closely related to L-arginine, a conditionally-essential amino acid. … Asymmetric dimethylarginine (ADMA) is a naturally occurring chemical found in blood plasma.

  3. Drug

    Pheneticillin

    go.drugbank.com/drugs/DB13337
    Approved

    Pheneticillin (or phenethicillin) is a penicillin antibiotic which is approved for use internationally.

  4. Drug

    Butaperazine

    go.drugbank.com/drugs/DB13213
    Approved

    Butaperazine was approved in 1967 [L5143], and possibly discontinued in the 1980s [T397].

  5. Drug

    Taranabant

    go.drugbank.com/drugs/DB06624
    Investigational

    Categories: Cannabinoid Receptor Agonists
  6. Drug

    Anacetrapib

    go.drugbank.com/drugs/DB06630
    Investigational

  7. Drug

    Valrocemide

    go.drugbank.com/drugs/DB06657
    Experimental

  8. Drug

    GMK

    go.drugbank.com/drugs/DB06661
    Experimental

    GMK vaccine (a ganglioside conjugate vaccine coupled to keyhole limpet hemocyanin and formulated with the adjuvant QS-21) for the potential treatment of melanoma

  9. Drug

    BBM-H901

    go.drugbank.com/drugs/DB17704
    Investigational

    BBM-H901 is a liver-tropic adeno-associated viral (AAV) vector carrying cassette coding hyperactive Padua factor IX (FIX) protein. It is being investigated for the treatment of hemophilia B.[A259048]

  10. Drug

    GO-203-2C

    go.drugbank.com/drugs/DB15008
    Investigational

    GO-203-2C is under investigation in clinical trial NCT02204085 (A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia).